Hepatocellular carcinoma (HCC) is one of the most common and aggressive human
malignancies. Recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) …

Regarding the multimechanistic nature of cancers, current chemo‐or radiotherapies often
fail to eradicate disease pathology, and frequent relapses or resistance to therapies occur …

In recent studies, we and others showed that autophagy is critical to estrogen receptor
positive (ER+) breast cancer cell survival and the development of antiestrogen resistance …

Proteasome inhibitors have been described as an important target for cancer therapy due to
their potential to regulate the ubiquitin-proteasome system in the degradation pathway of …

[Background]: Proteasome inhibition represents a promising novel anticancer therapy, and
bortezomib is a highly selective reversible inhibitor of the proteasome complex. Acute …

Background Survivin is known playing a role in drug resistance. However, its role in
bortezomib-mediated inhibition of growth and induction of apoptosis is unclear. There are …

The proteasome inhibitor bortezomib (BZ) has shown promising results in some types of
cancer, but in others it has had minimal activity. Recent studies have reported enhanced …

Introduction Notch is a family of transmembrane protein receptors whose activation requires
proteolytic cleavage by γ-secretase. Since aberrant Notch signaling can induce mammary …

Colorectal cancer is a major cancer type worldwide. 5-fluorouracil, often given with
leucovorin, is the most commonly used drug in colorectal cancer chemotherapy, yet …

Estrogen receptor-α (ERα) is a major therapeutic target of hormonal therapies in breast
cancer, and its expression in tumors is predictive of clinical response. Protein levels of ERα …